Walgreens, Rite Aid push back merger date
Walgreens Boots Alliance and Rite Aid Corp. have issued a joint announcement stating that the two companies have mutually agreed to extend their merger agreement end date to Jan. 27. Read More »
Walgreens Boots Alliance and Rite Aid Corp. have issued a joint announcement stating that the two companies have mutually agreed to extend their merger agreement end date to Jan. 27. Read More »
Walgreens has installed more than 500 safe medication disposal kiosks at pharmacy locations across 35 states and in Washington, D.C., reaching the goal it set out to achieve. Read More »
UnitedHealthcare's 2.4 million clients enrolled in its employer-sponsored health plans will soon be able to access Real Appeal, an online weight-loss program that is personalized, interactive and uses personal coaches and an internet television show that inspires individuals to be active, get healthy and lose weight. Read More »
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended that Opdivo from Bristol-Myers Squibb Co. be approved to treat relapsed or refractory classical Hodgkin lymphoma in adult patients who have previously received autologous stem cell transplant and been treated with brentuximab vedotin. Read More »
Walgreens customers shopping in stores in the southeast United States can make donations to the American Red Cross Relief Fund to help the victims of Hurricane Matthew. Read More »
Lundbeck's Carnexiv injection -- an orally administered replacement therapy for short-term use to treat adults with specific types of seizures -- has been approved by the U.S. Food and Drug Administration. Read More »
In the wake of Hurricane Matthew bearing down on the East Coast, Walgreens is reminding its pharmacy patients about how important prescription preparedness is in times like these. Read More »
Walgreens will recognize approximately 27,000 pharmacists serving communities across the country in celebration of American Pharmacists Month. Read More »
AbbVie's investigational, pan-genotype regimen of gelcaprevir (ABT-493) and pibrentasvir (ABT-530) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration. Read More »
Amgen's Phase 3 erenumab clinical trial has turned in positive results. Read More »
The U.S. Food and Drug Administration has approved Amgen’s AMJEVITA for the treatment of seven different inflammatory diseases. Read More »
Apintyx Inc. will develop its lead compound, NYX-2925, to treat neuropathic pain linked to diabetic peripheral neuropathy. Read More »
AbbVie recently announced that the small molecule active pharmaceutical ingredient (API) facility constructed at its Singapore manufacturing site is now open. Read More »
Abbott announced this week that its FreeStyle Libre Pro system, a groundbreaking continuous glucose monitoring (CGM) system designed for patients with diabetes, has been approved by the U.S. Food and Drug Administration (FDA).re Read More »
Amgen recently reported top-line results of its Phase 3 CLARION trial that was designed to assess KYPROLIS (carfilzomib), melphalan and prednisone (KMP), Amgen's new investigational regimen, while comparing it to Velcade (bortezomib). Read More »
AbbVie recently released new data from its Phase 3 GARNET study involving the combination of VIEKIRAX and EXVIERA that shows significant response rates after only eight weeks of the medication. Read More »
The trial will focus on idiopathic sudden sensorineural hearing loss (ISSNHL), also called sudden deafness. Read More »
AbbVie, a biopharmaceutical company that operates worldwide, has announced its 2016 Thriving Student Scholarship Contest. Read More »
Amgen has announced that the data from studies involving romosozumab and Prolia will be presented at the Annual Meeting of American Society for Bone and Mineral Research (ASBMR) on Sept. 16-19 in Atlanta, Georgia. Read More »
Amgen and Servier last week announced that their cardiovascular collaboration has seen an advancement due to Servier deciding to exercise its option for the commercialization of omecamtiv mecarbil in Europe for chronic heart failure. Read More »